# Allogene Targets Year-End 2027 Enrollment in ALPHA3 Study

By John Kim

Canonical URL: https://www.tokenpost.com/news/business/51695
Published: 2026-11-08T16:51:18.000Z
Updated: 2026-11-08T16:51:18.000Z
Section: Business

> The company plans a clinical update around midyear, with interim analysis and any unblinding under DSMB oversight.

Allogene Therapeutics, Inc. expects to finish enrollment in its ALPHA3 study by the end of 2027, setting a year-end target while planning a clinical update around midyear.

The company plans for the study’s interim analysis and any unblinding to proceed under DSMB oversight.